Cartesian Therapeutics, Inc. (RNAC): Capital Expenditures
$5.45M
Year ended 2025-12-31
$2.08M
Trailing 12 months to 2026-06-30
+65.6%
3-year compound annual growth
+46.3%
5-year compound annual growth
+16.7%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $5.45M | -40.0% | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | $9.09M | n/m | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | $206.0K | -82.8% | 2025-03-13, From 2023-01-01 |
| 2022-12-31 | $1.20M | +10.7% | 2024-03-07, From 2022-01-01 |
| 2021-12-31 | $1.08M | +33.1% | 2024-03-07, From 2021-01-01 |
| 2020-12-31 | $815.0K | n/m | 2023-03-02, From 2020-01-01 |
| 2019-12-31 | $47.0K | -94.7% | 2022-03-10, From 2019-01-01 |
| 2018-12-31 | $884.0K | +20.6% | 2021-03-12, From 2018-01-01 |
| 2017-12-31 | $733.0K | +25.1% | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | $586.0K | -49.6% | 2019-03-15, From 2016-01-01 |
| 2015-12-31 | $1.16M | +412.3% | 2018-03-15, From 2015-01-01 |
| 2014-12-31 | $227.0K | n/a | 2017-03-28, From 2014-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | 2025-12-31 | $5.45M | -40.0% |
| Upstream Bio, Inc. (UPB) | 2025-12-31 | $165.0K | -67.7% |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | $27.6K | +33.7% |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $279.0K | -36.7% |
| Lipocine Inc. (LPCN) | 2024-12-31 | $90.1K | +584.2% |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $59.3K | +54.4% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $0 | -100.0% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $88.0K | -67.2% |
| Ensysce Biosciences, Inc. (ENSC) | 2025-12-31 | $123.6K | n/a |
Compare RNAC, UPB, GOVX, CAMP side by side · Screen every company in Pharmaceutical Preparations ↗